CoChat

NCYM, a Cis-Antisense Gene of MYCN, Encodes a De Novo Evolved Protein That Inhibits GSK3β Resulting in the Stabilization of MYCN in Human Neuroblastomas

Open access
Suenaga, Yusuke, Islam, S. M. Rafiqul, Alagu, Jennifer, Kaneko, Yoshiki, Kato, Mamoru, Tanaka, Yukichi, Kawana, Hidetada, Hossain, Shamim, Matsumoto, Daisuke, Yamamoto, Mami, Shoji, Wataru, Itami, Makiko, Shibata, Tatsuhiro, Nakamura, Yohko, Ohira, Miki, Haraguchi, Seiki, Takatori, Atsushi, Nakagawara, Akira · 2014 · PLoS Genetics
Cited by 104

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

The rearrangement of pre-existing genes has long been thought of as the major mode of new gene generation. Recently, de novo gene birth from non-genic DNA was found to be an alternative mechanism to generate novel protein-coding genes. However, its functional role in human disease remains largely unknown. Here we show that NCYM, a cis-antisense gene of the MYCN oncogene, initially thought to be a large non-coding RNA, encodes a de novo evolved protein regulating the pathogenesis of human cancers, particularly neuroblastoma. The NCYM gene is evolutionally conserved only in the taxonomic group containing humans and chimpanzees. In primary human neuroblastomas, NCYM is 100% co-amplified and co-expressed with MYCN, and NCYM mRNA expression is associated with poor clinical outcome. MYCN directly transactivates both NCYM and MYCN mRNA, whereas NCYM stabilizes MYCN protein by inhibiting the activity of GSK3β, a kinase that promotes MYCN degradation. In contrast to MYCN transgenic mice, neuroblastomas in MYCN/NCYM double transgenic mice were frequently accompanied by distant metastases, behavior reminiscent of human neuroblastomas with MYCN amplification. The NCYM protein also interacts with GSK3β, thereby stabilizing the MYCN protein in the tumors of the MYCN/NCYM double transgenic mice. Thus, these results suggest that GSK3β inhibition by NCYM stabilizes the MYCN protein both in vitro and in vivo. Furthermore, the survival of MYCN transgenic mice bearing neuroblastoma was improved by treatment with NVP-BEZ235, a dual PI3K/mTOR inhibitor shown to destabilize MYCN via GSK3β activation. In contrast, tumors caused in MYCN/NCYM double transgenic mice showed chemo-resistance to the drug. Collectively, our results show that NCYM is the first de novo evolved protein known to act as an oncopromoting factor in human cancer, and suggest that de novo evolved proteins may functionally characterize human disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pgen.1003996

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

  • Neuroblastoma

    Matthay, K. K., Maris, J. M., Schleiermacher, G., Nakagawara, A., Mackall, C. L., Diller, L., & Weiss, W. A. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.78 · Cited by 1,419

    Self-citation
  • Splicing regulation by long noncoding RNAs

    Romero-Barrios, N., Legascue, M. F., Benhamed, M., Ariel, F., & Crespi, M. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky095 · Cited by 310

  • De novo gene birth

    Van Oss, S. B., & Carvunis, A.-R. (2019) · PLOS Genetics · doi:10.1371/journal.pgen.1008160 · Cited by 301

  • Neuroblastoma

    Nakagawara, A., Li, Y., Izumi, H., Muramori, K., Inada, H., & Nishi, M. (2018) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyx176 · Cited by 197

    “N-Myc OCT4 LIN28B GSK3β let-7 N-CYM AURKA AKT PI-3K ALK Symmetric cell division Asymmetric cell division Cancer stemness SOX2 NANOG Potential tumor suppressor Oncogenic protein Stemness factor Cell Growth Figure 4.”
    InfluentialSelf-citation
  • Origins of De Novo Genes in Human and Chimpanzee

    Ruiz-Orera, J., Hernandez-Rodriguez, J., Chiva, C., Sabidó, E., Kondova, I., Bontrop, R., Marqués-Bonet, T., & Albà, M. M. (2015) · PLOS Genetics · doi:10.1371/journal.pgen.1005721 · Cited by 160

    “One example is the hominoid-specific antisense gene, NCYM, which is over-expressed in neuroblastoma; this gene inhibits the activity of glycogen synthase kinase 3β (GSK3β), which targets NMYC for degradation [30].”
    Background

See all 104

Metadata

Authors
Suenaga, Y., Islam, S. M. R., Alagu, J., Kaneko, Y., Kato, M., Tanaka, Y., Kawana, H., Hossain, S., Matsumoto, D., Yamamoto, M., Shoji, W., Itami, M., Shibata, T., Nakamura, Y., Ohira, M., Haraguchi, S., Takatori, A., & Nakagawara, A.
Venue
PLoS Genetics
Published
2014-01-02
Volume
10
Issue
1
Pages
e1003996
ISSN
  • 1553-7390 (ISSN-L)
  • 1553-7404
OpenAlex
W2019017190
Cited by
104
References
8
FWCI
4.46
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: NCYM, a Cis-Antisense Gene of MYCN, Encodes a De Novo Evolved Protein That Inhibits GSK3β Resulting in the Stabilization of MYCN in Human Neuroblastomas. https://app.cochat.ai/papers/10.1371/journal.pgen.1003996
The paper
Suenaga, Y., Islam, S. M. R., Alagu, J., Kaneko, Y., Kato, M., Tanaka, Y., Kawana, H., Hossain, S., Matsumoto, D., Yamamoto, M., Shoji, W., Itami, M., Shibata, T., Nakamura, Y., Ohira, M., Haraguchi, S., Takatori, A., & Nakagawara, A. (2014). NCYM, a Cis-Antisense Gene of MYCN, Encodes a De Novo Evolved Protein That Inhibits GSK3β Resulting in the Stabilization of MYCN in Human Neuroblastomas. PLoS Genetics. https://doi.org/10.1371/journal.pgen.1003996

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.